SYNTHESIS, CHARACTERIZATION, AND IN VITRO ANTIMALARIAL ACTIVITY OF DIHYDROXYLATION DERIVATIVES OF TRICLOSAN by FITRIANA, WAHYU et al.
International Journal of Applied Pharmaceutics
ISSN - 0975 - 7058 Vol 12, Special Issue 1, 2020
SYNTHESIS, CHARACTERIZATION, AND IN VITRO ANTIMALARIAL ACTIVITY OF 
DIHYDROXYLATION DERIVATIVES OF TRICLOSAN
WAHYU FITRIANA1, ARRY YANUAR1*, ADE ARSIANTI2, HIROKI TANIMOTO3,  KIYOMI KAKIUCHI3
1Laboratory of Biomedical Computation and Drug Design, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia. 
2Department of Chemistry, Faculty of Medicine, Universitas Indonesia, Salemba, Jakarta 10430, Indonesia. 3Synthetic Organic Chemistry, 
Graduate School of Materials Sciences, Nara Institute of Science and Technology, Takayamacho, Ikoma, Nara, Japan. 
Email: arry.yanuar@ui.ac.id
Received: 02 October 2019, Revised and Accepted: 24 December 2019
ABSTRACT
Objective: The emergence of malaria as a global health problem over the past few decades, accompanied by the rise of chemoresistant strains of 
Plasmodium falciparum, has emphasized the need for the discovery of new therapeutic drugs against this disease. In this study, enantiomerically 
enriched (enantioenriched) analogs of triclosan were synthesized and evaluated for antimalarial activity against P. falciparum cultures.
Methods: Enantioselective dihydroxylation of the olefin in amide seven was performed efficiently using chiral quinine ligand (DHQ)2PHAL to yield 
enantioenriched dihydroxy propionamide derivative (+)-1 in moderate yields. In a similar way, the chiral quinidine ligand (DHQD)2PHAL was used as 
stereoselectivity agent yielded the desired enantioenriched (−)-1. The enantioenriched products were used for further in vitro assay, and accordingly the 
percent enantiomeric excess (% ee) was not determined. The structures of compounds were proven by spectral data (1H NMR, 13C NMR, and mass spectra).
Results: The phenol moiety at the C1 position of triclosan was chemically substituted with a methoxy group, in conjunction with an introduced 
stereocenter in a 2,3-dihydroxy-propionamide group at C2’ position. Unmodified triclosan inhibited the P. falciparum cultures with an IC50 value of 
27.2 µM. By contrast, the triclosan analogs, compounds (+)-1 and (−)-1, inhibited the P. falciparum cultures with IC50 values of 0.034 and 0.028 µM, 
respectively.
Conclusion: Collectively, our preliminary in vitro results suggest that these triclosan analogs have potent antimalarial activity and represent a 
promising new treatment strategy on further development.
Keywords: Triclosan, Synthetic analogs, Plasmodium falciparum, Antimalarial.
INTRODUCTION
To date, malaria remains one of the most devastating diseases of 
tropical and subtropical countries and is caused by the protozoan 
parasites of the Plasmodium genus. Worldwide, malaria causes over 
500 million new cases each year, with approximately 3 billion people 
living under the threat of malaria. The disease results in as many as 
2.7 million deaths annually, with children mostly affected. In addition, 
malaria has a striking correlation with social and economic disruption 
on a grand scale [1-5].
Chemoresistance is of increasing concern, primarily for Plasmodium 
falciparum, the parasite responsible for cerebral malaria, which is the 
most serious type of malaria infection. Indeed, this chemoresistance is 
believed to be a major factor in the worldwide upsurge of malaria [6]; 
therefore, there is an urgent need for new and potent antimalarial 
treatments [7].
The trichlorinated biphenyl ether triclosan [5-chloro-2-(2,4-dichloro-
phenoxy) phenol ether] (Fig. 1) is an antimicrobial component sometimes 
added to consumer products such as toothpastes, mouthwashes, 
deodorant soaps, lotions, and children toys [8]. Nevertheless, FDA 
nowadays has a restriction on triclosan as the emerging resistance 
issues. Triclosan’s effectiveness as an antimicrobial agent is believed 
to be due to its ability to inhibit the enzyme enoylacyl carrier protein 
reductase, which is involved in bacterial lipid biosynthesis [9-11]. 
In vitro studies confirm that triclosan is effective at killing P. falciparum 
and curing mice infected with the rodent malaria species Plasmodium 
berghei, as well as acute bacterial infection [12,13]. Appropriation as 
their potential efficacy against malaria parasites needs to be developed 
steadily to get the structure that is pharmacologically suitable for use 
in humans.
Continuing the work of earlier studies attempting to identify new and 
potent antimalarial treatments [14-20], in this study, we synthesized 





All starting materials were obtained from Sigma-Aldrich, Wako Pure, 
or Tokyo Chemical Industries and used as supplied. Solvents for 
chemical synthesis were acquired from commercial sources and used 
without further purification unless otherwise stated. Flash column 
chromatography was performed using Merck silica gel 60, whereas 
reactions and chromatography fractions were performed using Merck 
thin-layer chromatography (TLC) plates 60 F254. Compounds were 
visualized by an ultraviolet lamp (254 and 360 nm). Melting points 
(°C) were determined with a Yanaco micro melting point apparatus and 
remained uncorrected. Specific rotation, [α]D, was measured on a Jasco 
Digital Polarimeter. Mass analysis was performed with an electrospray 
mass JEOL JMS-AX 700 spectrometer, and gas chromatography was 
coupled with a mass spectrometer of high-resolution. 1H and 13C NMR 
spectral analyses were performed on a JEOL JNM-ECP500 (500 MHz), 
with tetramethylsilane as the internal standard. Chemical shifts are 
reported in units of (δ) ppm. The following abbreviations were used 
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to explain the multiplicities: s, singlet; d, doublet; t, triplet; dd, double 
doublet; m, multiplet, and br, broad.
4-Chloro-1-fluoro-2-nitro-benzene (3)
A three-neck round-bottomed flask was charged with m-CPBA (3.16 g, 
14.5 mmol) dissolved in 1,2-dichloroethane (13 mL). The mixture was 
refluxed until it reached the boiling point of the solvent (84°C). To 
this mixture, a solution of 5-chloro-2-fluoro-phenylamine 2 (0.4 mL, 
3.5 mmol) in 1,2-dichloroethane (3.5 mL) was added dropwise using 
an addition funnel. After 3 h, the reaction mixture was cooled to room 
temperature (RT), diluted with CHCl3 and washed with a 5% NaOH 
solution, water, and diluted HCl to remove excess and unreacted starting 
materials. The organic layer was then washed in a brine solution and 
dried over anhydrous MgSO4. The product 3 (yellow liquid) containing 
trace m-chloroquine acid was used for the further reaction without 
purification (425 mg, 73%). TLC Rf 0.42 (hexane/EtOAc 20:1); 1H NMR 
(CDCl3, 500 MHz) δ: 8.00 (dd, J=2.7 and 6.4 Hz, 1H), 7.55 (dq, J=8.9 and 
2.2 Hz, 1H), 7.22 (dt, J=9.6 and 4.0 Hz, 1H). HRMS-EI+ m/z: Calcd for 
C6H3ClFNO2: 174.9836 [M]+; found: 174.9829.
4-Chloro-1-(2’-methoxy-4’-chloro-phenoxy)-2-nitro-benzene (5)
To a solution of compound 3 (0.30 g, 1.72 mmol) and 4-chloro-2-
methoxy-phenol 4 (0.2 mL, 1.65 mmol) in dimethylformamide (DMF) 
(3.5 mL), anhydrous K2CO3 (0.5 g) and a catalytic amount of 18-crown-6 
were added and stirred in an oil bath at 60°C for 3 h. After the reaction 
was complete, the reaction mixture was cooled to RT and diluted with 
toluene. The organic layer was then washed with a 10% NaOH solution, 
water, and a brine solution and then dried over anhydrous MgSO4. The 
crude product was purified on silica using a 15–30% toluene/hexane 
mixture to yield 376 mg (73%) of the compound 5 (yellow liquid). 
TLC Rf 0.31 (hexane/EtOAc 20:1); 1H NMR (CDCl3, 500 MHz) δ: 7.93 
(d, J=3.1 Hz, 1H), 7.38 (dd, J=2.7 and 8.9 Hz, 1H), 6.96–7.02 (m, 3H), 
6.76 (d, J=9.2 Hz, 1H), 3.76 (s, 3H); 13C NMR (CDCl3, 125 MHz) δ: 151.48, 
149.89, 141.28, 139.63, 133.81, 131.51, 127.02, 125.26, 122.49, 120.96, 
118.89, 113.56, 55.96. HRMS-ESI+ m/z: Calcd for C13H9Cl2NO4: 335.9806 
[M+Na]+; found: 335.9806.
5-Chloro-2’-(4’-chloro-2-methoxy-phenoxy)-phenylamine (6)
Tin metal (0.18 g) and conc. HCl (0.5 mL) were added to the solution 
of compound 5 (0.10 g, 0.33 mmol) in EtOH (2 mL) in a 100 mL round-
bottomed flask. The mixture solution was refluxed at 100°C for 3 h and 
then cooled to RT, to which a solution of 30% NaOH was added until the 
white precipitate was dissolved. The solution was then extracted with 
ether, washed with water and brine solution, and dried over anhydrous 
MgSO4. The crude product was purified on a silica gel column using 
40–70% toluene/hexane to yield 62% (58 mg) of compound 6. Off-
white solid, m.p: 67°C. TLC Rf 0.45 (hexane/EtOAc 4:1); 1H NMR 
(CDCl3, 500 MHz) δ: 6.96 (d, J=2.4 Hz, 1H), 6.85 (d, J=2.4 Hz, 1H), 6.84 
(d, J=2.4 Hz, 1H), 6.78 (d, J=8.6 Hz, 1H), 6.74 (d, J=1.8 Hz, 1H), 6.60 
(d, J=3.1 Hz, 1H), 3.94 (s, 2H [NH2]), 3.76 (s, 3H); 13C NMR (CDCl3, 125 
MHz) δ: 150.96, 144.07, 142.49, 138.92, 129.16.81, 129.11, 120.73, 
119.59, 118.94, 118.04, 115.76, 113.15, 56.12. HRMS-EI+ m/z: Calcd for 
C13H11Cl2NO2: 283.0167 [M]+; found: 283.0164.
N-[5-Chloro-2-(4-chloro-2-methoxy-phenoxy)-phenyl]-acrylamide (7)
To a solution of triethylamine (0.03 mL, 0.42 mmol), dry THF (1.5 mL) 
under N2 was added to give the amine compound 6 (50 mg, 0.14 mmol) 
at 0°C. After stirring for 15 min, acryloyl chloride (0.02 mL, 0.28 mmol) 
was introduced, and the mixture was allowed to warm to RT for 3 h. The 
mixture was then diluted with EtOAc, 1 M HCl, water, saturated NaHCO3, 
and a brine solution. The solution was then dried over anhydrous 
MgSO4, and the crude extract was purified by column chromatography 
on a silica gel using 10:1 hexane/EtOAc to obtain product 7 (45 mg, 
76%) as an off-white liquid. TLC Rf 0.37 (hexane/EtOAc 4:1); 1H NMR 
(CDCl3, 500 MHz) δ: 8.59 (s, 1H [NH]), 8.12 (s, 1H), 6.94 (m, 4H), 6.59 (d, 
J=9.2 Hz, 1H), 6.44 (t, J=8.2 Hz, 1H), 6.30 (dd, J=16.8 and 10.1 Hz, 1H), 
5.78 (dd, J=10.4 and 1.2 Hz, 1H), 3.78 (s, 3H); 13C NMR (CDCl3, 125 MHz) 
δ: 163.33, 151.61, 145.04, 142.46, 130.96, 129.42, 128.41, 128.20, 
123.47, 122.30, 120.99, 120.55, 116.03, 113.43, 56.02. A quaternary 
carbon atom that binds chlorine appeared as a single peak. HRMS-EI+ 
m/z: Calcd for C16H13Cl2NO3: 337.0272 [M]+; found: 337.0273.
(Method e) enantioenriched from chiral ligand (DHQ)2PHAL ((+)-1)
To a stirred solution of amide 7 (0.20 g, 0.60 mmol) in 16 m t-BuOH: H2O 
(1:1), K3Fe(CN)6 (1.17 g, 3.56 mmol) was added, along with anhydrous 
K2CO3 (0.5 g, 3.56 mmol), NaHCO3 (0.2 g, 3.56 mmol), and (DHQ)2PHAL 
(0.14 g, 30 mol%). The resulting mixture was stirred at RT for 10 min, 
and the solution was then cooled to 0°C. To this solution, we added 
OsO4 (40 mol%) and continued at 0°C for 4 h. The reaction was quenched 
by the addition of water (15 mL) and Na2SO3 (0.5 g, 4.0 mmol). The 
resulting mixture was extracted using CH2Cl2. The combined CH2Cl2 
layers were then dried over anhydrous MgSO4, filtered, and concentrated 
under reduced pressure. The crude residue was then purified by column 
chromatography on silica (gradient elution 99:1–98:2, CHCl3:CH3OH) to 
give an enantiomer mixture of products (+)-1 (165 mg, 75%) as a white 
solid, m.p.: 162°C, [α]D27 (+) 4.0*, (c=0.40). TLC Rf 0.3 (CHCl3/CH3OH 
96:4); 1H NMR (CDCl3, 500 MHz) δ: 8.42 (d, J=2.4 Hz, 1H), 7.16 (d, J=1.8 Hz, 
1H), 7.09 (d, J=8.6 Hz, 1H), 6.96–7.00 (m, 2H), 6.62 (d, J=8.6 Hz, 1H), 4.21 
(t, J=4.0 Hz, 1H), 3.83 (t, J=2.4 Hz, 2H), 3.77 (s, 3H); 13C NMR (CDCl3, 125 
MHz) δ: 173.16, 153.57, 147.43, 143.89, 132.34, 129.94, 128.75, 124.86, 
124.00, 121.98, 121.19, 117.17, 114.83, 74.63, 65.20, 56.70. HRMS-EI+ 
m/z: Calcd for C16H15Cl2NO5: 371.0327 [M]+; found: 371.0322.
(Method f) enantioenriched from chiral ligand (DHQD)2PHAL ((−)-1)
To a stirred solution of amide 7 (0.20 g, 0.60 mmol) in 16 mL t-BuOH: H2O 
(1:1), K3Fe(CN)6 (1.17 g, 3.56 mmol) was added, along with anhydrous 
K2CO3 (0.5 g, 3.56 mmol), NaHCO3 (0.2 g, 3.56 mmol), and (DHQ)2PHAL 
(0.14 g, 30 mol%). The resulting mixture was stirred at RT for 10 min, 
and this solution was then cooled to 0°C. To this solution, we added 
OsO4 (40 mol%) and continued stirring at 0°C for 4 h. The reaction was 
Fig. 1: Triclosan and the designed derivatives
Fig. 2: Reagents and conditions: (a) m-CPBA, 1,2-dichloroethane, 
84°C, 73%; (b) K2CO3/DMF, 18-crown-6, 60°C, 73%; (c) Sn/Conc. 
HCl, EtOH, 100°C, 62%; (d) acryloyl chloride, Et3N/THF, N2 (g), 0°C, 
76%; (e) (DHQ)2PHAL, K3Fe(CN)6, K2CO3, NaHCO3, OsO4, RT to 0°C, 
75%; (f) (DHQD)2PHAL, K3Fe(CN)6, K2CO3, NaHCO3, OsO4, RT to 0°C, 
70%
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quenched by the addition of water (15 mL) and Na2SO3 (0.5 g, 4.0 mmol). 
The resulting mixture was extracted using CH2Cl2. The combined CH2Cl2 
layers were dried over anhydrous MgSO4, filtered, and concentrated 
under reduced pressure. The crude residue was then purified by column 
chromatography on silica (gradient elution 100:0–98:2, CHCl3:CH3OH) to 
give an enantiomer mixture of products (–)-1 (154 mg, 70%) as a white 
solid, m.p.: 158°C, [α]D27 (−) 3.2*, (c=0.37). TLC Rf 0.32 (CHCl3/CH3OH 
96:4); 1H NMR (CDCl3, 500 MHz) δ: 8.42 (d, J=2.4 Hz, 1H), 7.16 (d, J=2.4 Hz, 
1H), 7.09 (d, J=8.6 Hz, 1H), 6.95–7.00 (m, 2H), 6.62 (d, J=8.6 Hz, 1H), 4.22 
(t, J=4.3 Hz, 1H), 3.83 (t, J=2.4 Hz, 2H), 3.77 (s, 3H); 13C NMR (CDCl3, 125 
MHz) δ: 173.16, 153.56, 147.41, 143.89, 132.34, 129.94, 128.74, 124.86, 
123.99, 121.97, 121.19, 117.17, 114.82, 74.62, 65.19, 56.69. HRMS-EI+ 
m/z: Calcd for C16H15Cl2NO5: 371.0326 [M]+; found: 371.0322.
Determination of the antimalarial activity
The antimalarial activity of the synthesized molecules was evaluated 
against P. falciparum strain 3D7 (Eijkman Institute for Molecular Biology, 
Indonesia) using sensitive chloroquine and the procedure described 
by Budimulya [21]. P. falciparum 3D7 in human red blood cells (RBCs) 
(3% initial parasite density, and 4% hematocrit) was cultured with 
the test compound (added as 150 µL dimethyl sulfoxide solution) in 
1350 µL of the medium (RPMI-1640, 25 µg/mL gentamycin, 50 µg/mL 
hypoxanthine, 25 mM Hepes buffer, 25 mM NaHCO3, and 10% human 
serum) using a 96-well microtiter plate at 37°C. Tests were carried out 
simultaneously for three molecules in duplicate. A sealed incubation 
chamber continuously gassed with a mixture of 2% O2, 8% CO2, and 
90% N2 was used. Increases in the proportion of infected RBCs were 
assessed at the end of the 48 h incubation period in control samples 
and at various concentrations of each drug using Giemsa stained 
slides. Control samples contained P. falciparum 3D7 without any test 
compounds. The growth of the parasite was monitored by performing 
a blood smear fixed with MeOH and stained with a Giemsa stain. The 
antimalarial activity of each compound was expressed as an IC50 value, 
defined as the concentration of the compound causing 50% inhibition 
of parasite growth relative to the untreated control.
RESULTS AND DISCUSSION
Compound 6 was prepared by three chemical reactions in accordance 
with a previously reported procedure [18] (Fig. 2). Primary amine 2 
in a commercially available form was oxidized with m-CPBA to form 
the corresponding nitrobenzene 3. Diphenyl ether derivative 5 was 
obtained by the coupling of the methoxy phenol 4 and nitrobenzene 3 
in the presence of K2CO3 and 18-crown-6 in DMF. The nitro group in 5 
was easily reduced with Sn/HCl by reflux in ethanol to afford the known 
compound 6.
In dry THF, the amidation of 6 with acryloyl chloride afforded the 
desired amide 7. The amidation of 6 with acrylic acids and carbodiimide 
reagents was also attempted but was unsuccessful to give the desired 
amide 7. Diamagnetic anisotropy, which is commonly associated with 
asymmetric monosubstituted alkenes, appeared on the terminal olefin 
group of compound 7. Each of the three hydrogen atoms contributed 
inequivalently to form an exceptional splitting pattern (Fig. 3). The 
resulting peak of each hydrogen atom was expressed in terms of 
a chemical shift 6.44 ppm (t, J=8.2 Hz), 6.30 ppm (dd, J=16.8 Hz and 
10.1 Hz), and 5.78 ppm (dd, J=10.4 Hz and 1.2 Hz).
Enantioselective dihydroxylation of the olefin in amide 7 was performed 
efficiently using the Sharpless et al. asymmetric dihydroxylation 
reaction [22] and the chiral quinine ligand (DHQ)2PHAL, to yield 
enantioenriched dihydroxy propionamide derivative (+)-1 in moderate 
yields, attributed to a specific rotation, [α] (+) 4.0 (c=0.40, in CH3OH). 
Similarly, when the catalyst was changed to the quinidine derivative 
(DHQD)2PHAL, the opposite selectivity was observed, and it yielded 
the desired enantioenriched (−)-1 with a specific rotation, [α] (−) 3.2 
(c=0.37, in CH3OH). As reported by Sharpless et al. and associates in 
2001, these chiral ligands have proven to be superior to others for 
the dihydroxylation of olefins with aliphatic substituents [22]. The 
enantioenriched products were used for further in vitro assays, with the 
percent of enantiomeric excess (% ee) not determined. The structures 
of compounds were proven by spectral data (1H NMR, 13C NMR, and 
mass spectra).
All inhibitors were tested for their inhibition of growth of the blood 
stages of the parasite P. falciparum 3D7 culture for 48 h in human blood. 
The activities of the test compounds compared with those of reference 
drugs are presented in Table 1. From the biological test results 
generated, analog (−)-1 appears to possess activity nearly as active as 
analog (+)-1 at lower micromolar concentrations. Qualitatively, this is 
understood by the fact that the specific configurations (R, rectus and 
S, sinister) of the enantiomers of these analogs are both active. This is 
likely because each of these cinchona ligands produced high enantiomer 
excess of a certain configuration [23].
Our results indicate that both of the enantioenriched analogs (+)-1 
and (–)-1 of the 2’-chloro- and phenol-modified series exhibited better 
antimalarial activity profiles than the unsubstituted triclosan. Hence, 
triclosan inhibited P. falciparum cultures with an IC50 of 27.2 µM, 
whereas the analogs (+)-1 and (–)-1 inhibited the cultures with IC50 
values of 0.034 and 0.028 µM, respectively. In comparison, the IC50 value 
for chloroquine, a well-established drug for the treatment of malaria, is 
0.0003 µM. Therefore, given our activity results, it will be necessary to 
Fig. 3: The splitting pattern of hydrogen atoms on the vinyl group of amide 7
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add more chemical attributes to these molecules to make them active at 
the nanomolar level.
CONCLUSION
We have synthesized novel triclosan analogs that appear to have potent 
antiplasmodial activity. The design of these new analogs was initiated 
with the introduction of chirality, and the analogs were synthesized in 
five steps to obtain a moderate yield. These favorable preliminary in vitro 
results demonstrating the potency of the synthesized compounds, (+)-1 
and (–)-1, indicate that these compounds, particularly with additional 
modification, may prove to be promising antimalarial leads based 
on the concept of drug enantioselectivity. Future efforts will seek to 
define the mode of action of these potent antimalarials while further 
optimizing their activity with a wider range of substituent groups that 
may offer improved antimalarial activity.
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